TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A U.S. real-world analysis of 339,092 people with multiple sclerosis found that GLP-1 drug exposure was associated with lower rates of steroid-treated relapses, optic neuritis and other recorded outcomes. The observational study cannot show that the drugs caused the differences; researchers say prospective studies are needed.
A U.S. real-world study of 339,092 people with multiple sclerosis found that those exposed to GLP-1 receptor agonists had lower recorded rates of steroid-treated relapses, optic neuritis and other outcomes than patients without exposure. The analysis, presented by Mahsa Khayat-Khoei at the MSToronto2026 meeting, shows an association, not proof that the drugs prevent MS activity.
Across the study’s 12-year observation period, acute steroid-treated relapses were recorded in 1.85% of the GLP-1-exposed group and 4.84% of the unexposed group. The report gave a relative risk of 2.62 (95% CI 2.28-3.03), expressing the comparison between groups. Optic neuritis was recorded in 1.46% versus 2.56%, respectively, with a reported relative risk of 1.78 (95% CI 1.48-2.09).
The study also reported lower percentages of demyelinating events among exposed patients, at 3.48% versus 7.01%, and gait abnormalities, at 10.46% versus 16.15%. Fatigue was recorded in 11.87% versus 17.55%, while depression was recorded in 19.34% versus 26.38%. The report said these comparisons were statistically significant, with P<0.00001. They are database-recorded outcomes, not evidence that GLP-1 drugs directly changed the course of MS.
Researchers used the TriNetX U.S. research network and identified patients through ICD-10 codes. Of the 339,092 people included, 14,300 had GLP-1 drug exposure; 82% of that exposed group were women. The team used propensity-score matching for factors including age, sex and comorbidities. Still, the groups differed before matching: exposed patients had a higher mean BMI and more recorded obesity and type 2 diabetes.
Why the MS Findings Matter
The findings add a large real-world comparison to questions about whether GLP-1 receptor agonists might have effects relevant to neurological conditions beyond their established uses in diabetes and obesity. Lower recorded rates across several MS outcomes give researchers a reason to test the association more directly.
But treatment decisions cannot be drawn from this analysis. GLP-1 exposure may be linked to differences in health, access to care, prescribing, or other factors that are not fully captured in a database. The results do not establish that starting a GLP-1 drug would reduce relapses, nor do they show how these medicines compare with MS therapies in a controlled trial.
Products Worth Considering
Garmin Venu 3 Fitness Smartwatch, 45 mm, Black
BowFlex Results Series SelectTech Dumbbells
Bowflex SelectTech 840 Adjustable Kettlebell
As an affiliate, we earn on qualifying purchases.
How Researchers Built the Comparison
The analysis included a subgroup of 30,934 people treated with ocrelizumab, a B-cell therapy for MS; 1,953 of them had GLP-1 exposure. The subgroup analysis covered 10 years, reflecting that ocrelizumab has been available since 2017. The reported pattern was similar, with the largest relative-risk comparisons for acute steroid-treated relapses and optic neuritis. These subgroup results remain observational.
Khayat-Khoei said the team also examined outcomes over 21 years and found similar patterns, though the report’s principal results focused on 12 years. She described GLP-1 drugs as a possible research avenue because of proposed links to inflammation and neuronal survival. A biological explanation, however, is not established by the database findings.
“Prospective studies are needed to determine whether GLP-1 receptor agonists have disease-modifying or neuroprotective effects in MS.”
— Mahsa Khayat-Khoei, University of California Riverside
What the Database Cannot Establish
The study does not establish whether GLP-1 drugs caused the lower rates or whether other differences between patients explain some or all of the association. Propensity matching can address measured characteristics, but it cannot remove the limits of an observational database or account for every possible confounder. The source report does not provide enough detail to assess all aspects of outcome validation, medication duration, adherence or individual drug effects.
It is also unclear whether the association applies equally across GLP-1 medicines, doses, patient groups or stages of MS. The exposed group had substantially more obesity and type 2 diabetes before matching, reflecting how these drugs are commonly prescribed. The findings do not establish GLP-1 agonists as MS treatments, and the report gives no basis for patients to start, stop or change medication.
Prospective MS Studies Needed
Khayat-Khoei said prospective studies are needed to test whether GLP-1 receptor agonists have disease-modifying or neuroprotective effects in MS. Such research would need to clarify which patients and medicines are involved and track outcomes under a design that can better distinguish treatment effects from other differences.
A separate study mentioned in the report, the TAG-MS trial, is testing NLY01, a pegylated exenatide analogue, in people with progressive MS. It is examining whether the drug can lessen brain and retinal atrophy by reducing inflammation. That trial is a distinct line of investigation; its results were not reported as part of the TriNetX analysis. No results or timetable for a definitive prospective test of the broader GLP-1 association were provided.
Key Questions
Does this study show GLP-1 drugs prevent MS relapses?
No. It found lower recorded rates associated with exposure in an observational analysis. It cannot establish that the drugs caused the difference.
How many people were included?
The main analysis included 339,092 people with MS in a U.S. research network, including 14,300 with GLP-1 drug exposure.
Which outcomes were lower in the exposed group?
The report found lower recorded percentages for steroid-treated relapses, optic neuritis, demyelinating events, gait abnormalities, fatigue and depression. These are study comparisons, not proof of a treatment effect.
Can people with MS use these results to change medication?
No. The study does not establish GLP-1 drugs as MS treatment or provide individualized medical guidance. Patients should discuss medication decisions with a qualified health professional.
What research is needed next?
The study’s presenter called for prospective research to determine whether GLP-1 receptor agonists affect MS disease activity or neuroprotection. A separate trial is testing NLY01 in progressive MS.
Source: medpagetoday.com
